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SUMMARY
HPV infections are common in healthy women and
only rarely cause cervical cancer, suggesting that
individual genetic susceptibility may play a critical
role in the establishment of persistent HPV infection
and the development of cervical cancer. Here, we
provide convincing in vitro and in vivo evidence
showing that differential expression and activation
of YAP1 oncogene determine individual susceptibility
to HPV infection and cervical carcinogenesis. We
found that hyperactivation of YAP1 in mouse cervical
epithelium was sufficient to induce invasive cervical
cancer. Cervical epithelial cell-specific HPV16 E6/E7
and YAP1 double-knockin mouse model demon-
strated that high-risk HPV synergized with hyperacti-
vated YAP1 to promote the initiation and progression
of cervical cancer. Our mechanistic studies indicated
that hyperactivation of YAP1 in cervical epithelial
cells facilitated HPV infection by increasing the puta-
tive HPV receptor molecules and disrupting host cell
innate immunity. Our finding reveals an unconven-
tional mechanism for cervical carcinogenesis.
INTRODUCTION
Cervical cancer is themost common gynecologic cancer and the
fourth leading cause of cancer-related death in women world-
wide. According to the latest statistics of the International
Agency for Research on Cancer (IARC), approximately 527,000
women are diagnosed with cervical cancer, and an estimated
265,000 women die of this disease each year, equal to almost
one-tenth of global cancer deaths in women (Torre et al.,
2015). The increased use of the Pap test and intensive imple-
mentation of health education programs have reduced cervical
cancer death by more than 50% in the United States over the
past 40 years. Nevertheless, the National Cancer Institute esti-
mates that 250,000 women are living with cervical cancer in
the United States (Howlader et al., 2018). The treatment for cer-
vical cancer includes surgery, radiation, or concurrent chemora-
diation. However, the survival rates of advanced-stage and
recurrent cervical cancer patients are still very low. Cervical can-
cers of advanced stages and distant recurrence are currently
considered to be incurable. Effective new therapeutic options
are currently not available, because the detailed mechanism or
mechanisms underlying cervical cancer development and pro-
gression are unclear at present.
Because the majority of cervical cancer patients are positive
for human papillomavirus (HPV) DNA, it is widely accepted that
all cases of cervical cancer are caused by high-risk HPV (Wal-
boomers et al., 1999). However, although the lifetime risk for
HPV infection is more than 75% (Koutsky, 1997), only a very
small portion of women infected with HPV develop cancers
(Kulasingam et al., 2002), suggesting that HPV alone is not suffi-
cient for the malignant transformation of cervical epithelial cells.
Themolecular mechanism or mechanisms underlying the tumor-
igenesis of cervical epithelium are unclear.
The Hippo pathway is an evolutionarily conserved pathway
that controls organ development from the fruit fly to mammals
(Dong et al., 2007; Mo et al., 2014). Overall, the upstream core
kinases of the Hippo pathway, including FAT1/2/3/4, Nf2,
Mst1/2, Sav1, LATS1/2, and MOB1a/b, have been identified as
tumor suppressors, while the downstream effectors, mainly
YAP1 and TAZ (WWTR1) transcriptional co-activators, have
been described as oncoproteins (Pan, 2010; Zanconato et al.,
2016). Our previous studies showed that the Hippo/YAP
2636 Cell Reports 26, 2636–2650, March 5, 2019 ª 2019 The Author(s).
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Figure 1. Hyperactivation of YAP1 Induces Invasive Cervical Cancer in Mice
(A) A schematic diagram showing the transgenicmouse strains andbreeding procedures for generating KRT14-YAPS127Amice (micewith keratin 14 [KRT14]-driven
and tetracycline-induced expression of YAPS127A gene in cervical epithelium).
(B) Representative gel image showing PCRproducts (genotyping results) of wild-type (lane 3), KRT14-rtTA alone (lane 1), TRE-YAP alone (lane 4), and KRT14-rtTA
and TRE- YAPS127A co-expressed (lane 2) mice.
(C) Representative image showing the reproductive tract from KRT14-YAPS127A transgenic mice after induction of gene expression with doxycycline
(0.05 mg/mL) for 8 months. Note the invasion of cancer in the uterine and vaginal area (red arrow).
(legend continued on next page)
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signaling pathwaymay play a role in cervical carcinogenesis. We
found that YAP1, the major effector of the Hippo signaling
pathway, interacted with HPV16 E6 oncoprotein to drive the
initiation and progression of cervical cancer (He et al., 2015b).
Very recently, The Cancer Genome Atlas (TCGA) Research
Network published the most comprehensive cervical cancer
genome, analyzing results after sequencing tissues derived
from 228 primary cervical cancers (Cancer Genome Atlas
Research Network et al., 2017). The extended TCGA dataset
indicated that a gene cluster with high copy number alterations
mostly contained squamous tumors with amplification events
involving 11q22 (YAP1, BIRC2, and BIRC3) and 7p11.2 (EGFR).
These data strongly support a role of the Hippo/YAP1 pathway
in the development of cervical cancer. In the present study, we
successfully developed several transgenic mouse models indi-
cating that the Hippo/YAP1 pathway is at the center of cervical
carcinogenesis. We found that hyperactivation of YAP1 in the
cervical epithelial cells is sufficient to induce cervical squamous
cell carcinoma (CVSCC). We also found that hyperactivated
YAP1, by upregulating expression of the putative HPV receptors
and suppressing innate immunity, facilitates HPV infection of
cervical epithelial cells. HPV in turn synergizes with YAP1 to pro-
mote the initiation and progression of cervical cancer.
RESULTS
The Hippo/YAP Pathway Is Frequently Dysregulated in
Cervical Cancer Patients
To examine the role of the Hippo/YAP pathway in the develop-
ment of cervical cancer, we first analyzed the genomic data of
191 cervical cancer patients, which were deposited in TCGA
(Cancer Genome Atlas Research Network et al., 2017; Cerami
et al., 2012). The results showed that YAP1, the oncogenic
effector of the Hippo pathway, was frequently (11%) amplified,
while LATS1/2, MST1, and FATs, which are upstream tumor
suppressors of the Hippo pathway, were frequently deleted or
mutated in cervical cancer patients (Figure S1A). Importantly,
we found that the rates of overall survival and disease-free
survival of 74 patients with amplification of YAP1 or deletion
and/or mutation of tumor suppressors (FAT1/2/3/4, MST1/2,
LATS1/2) were significantly poorer than in 96 patients without
genomic alterations (Figures S1B and S1C), suggesting that
dysregulation of the Hippo/YAP pathway in patients is associ-
ated with poor outcomes. Consistent with these results,
immunohistochemistry (IHC) studies showed that both the im-
munosignal intensity and positivity of YAP1 protein significantly
increased with grades of cervical intraepithelial neoplasia (CIN)
(n = 7 for normal control, n = 28 for CIN1, n = 23 for CIN2, n = 29
for CIN3; Figures S2A–S2D). Cervical cancer tissues from
advanced-stage patients had higher expression levels and
more nuclear accumulation of YAP1 protein compared with
those from early-stage patients (n = 68; Figures S2A–2D), indi-
cating that the activity of YAP1 was elevated with cancer
progression.
Hyperactivation of YAP1 Is Sufficient to Induce Cervical
Cancer In Vivo
To examine whether hyperactivation of YAP1 plays a role in
cervical carcinogenesis, we generated a mouse model with cer-
vical epithelial cell-specific expression of YAPS127A (Figure 1A).
In these transgenic mice (hereafter referred to as KRT14-
YAPS127A), the expression of YAPS127A (constitutively active
YAP1) was under the control of the keratin 14 (KRT14) promoter
and doxycycline (Dox) availability, allowing inducible expression
of YAPS127A in mouse cervical epithelial cells (Figure 1A). After
PCR-based genotyping (Figure 1B), Dox-containing water was
used to replace the normal drinking water of 3-month-old control
(KRT14-rtTA or TRE-YAPS127A alone) and KRT14-YAPS127A
mice. We found that high concentration of DOX (2.0 mg/mL)
induced hyperplasia of squamous epithelium in multiple organs
within 2 weeks, leading to rapid death of these animals (Fig-
ure S3). However, when the concentration of Dox in drinking
water was reduced to 0.05 mg/mL, multi-organ hyperplasia
was significantly alleviated, but ectopic YAPS127A was still
expressed in CVSCCs (Figure 1E). As shown in Figure 1F, low
concentration of Dox-induced expression of YAPS127A resulted
in drastic hyperplasia of cervical epithelial cells within 2 months
in KRT14-YAPS127A mice but not in control mice. Most of
KRT14-YAPS127A mice developed invasive cervical tumors
after induction with 0.05 mg/ML Dox for 6–8 months (Figures
1C, 1D, and 1F). With the progression of cervical cancer, ureteral
obstruction, which is frequently present in advanced human cer-
vical cancer patients, was observed in some KRT14-YAPS127A
mice (Figure 1D). About 50% of KRT14-YAPS127A mice died after
13 months of induction of YAPS127A expression with Dox (Fig-
ure 1G). IHC analysis indicated that known protein biomarkers
currently available for cervical cancer subtype screening (Ki67,
P16INK4A, deltaNp63, EGFR, and Pan KRT) were highly ex-
pressed in cervical cancer tissues from the KRT14-YAPS127A
mice (Figure S4). No obvious difference was observed in the
TP53 protein levels between the control and cancerous cervical
tissues (Figure S4). These biochemical features support the
pathological conclusion that cancers in KRT14-YAPS127A mice
are CVSCC.
YAP1 Facilitates HPV Infection of Cervical Epithelial
Cells
Although our animal model showed that hyperactivation of YAP1
is sufficient to induce the development of CVSCC, the strong
epidemiological association between HPV infection and cervical
(D) A representative image showing the general anatomy of KRT14-rtTA control mice and KRT14-YAPS127A mice. Note the obstruction of the urination system
(the red arrow points to an enlarged bladder) caused by ureter blockage due to cervical tumor in KRT14-YAPS127A transgenic mice.
(E) Representative images showing expression of YAP1 protein in cervical tissues of control and KRT14-YAPS127A transgenic mice.
(F) Representative images showing H&E staining of cervical tissues form control and KRT14-YAPS127A transgenic mice. Note the cancer progression in the
cervical epithelium after doxycycline induction for 8 months. Scale bar: 500 mm.
(G) Kaplan-Meier curve showing survival rates of control mice (blue line, n = 12) and KRT14-YAPS127A mice (red line, n = 14) after doxycycline induction of YAP1
expression in cervical epithelial cells.
2638 Cell Reports 26, 2636–2650, March 5, 2019
A B
C D E
F G
IH
Figure 2. Hyperactivation of YAP1 Increases Susceptibility of Human Cervical Epithelial Cells to HPV Infection
(A) A schematic cartoon showing the natural process of HPV infection of human cervix. HPV infects basal epithelial cells when a wound is created in cervical
epithelium.
(legend continued on next page)
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cancer implies that HPV oncoproteins are involved in cervical
tumorigenesis. HPV primarily infects basal epithelial cells when
a wound is created in cervical tissue (Figure 2A). IHC showed
that YAP1 protein was highly expressed in cervical basal cells
in human and mouse cervix (Figure 2B). This coincidence sug-
gests that high YAP1 in the basal cells may facilitate HPV infec-
tion during wound healing process. Indeed, a wound-healing
assay using primary cultures of human cervical epithelial cells
(hCerECs) showed that in the ‘‘wound’’ area, YAP1 was predom-
inately localized to nuclei (active form of YAP1), while in the
non-wound area, YAP1 protein was almost evenly distributed
in cytoplasm and nucleus of hCerECs (Figure 2C). We then
used a HPV16 pseudovirion (HPV16 PsV) (Roberts et al., 2007)
to examine if YAP1 expression affected HPV infectivity. After
incubating hCerECs with HPV16 PsVs (MOI = 2.0) for 72 h,
GFP-positive cells were detected in the wound area (Figure 2D),
but few GFP-positive cells were found in the non-wound area
(Figures 2D and 2E). The signal intensity of GFP was also
much stronger in hCerECs in the wound area (Figure 2D).
Incubating hCerECs with HPV16 PsVs (MOI = 1.0) for 72 h in
the regular two-dimensional (2D) culture results in more GFP-
positive cells in hCerEC-YAP and hCerEC-YAPS127A cells
compared with hCerEC-MX control cells (Figures 2F and S5A).
In contrast, knockdown of YAP1 significantly reduced the
infectivity of HPV16 PsV in hCerECs after incubating with
HPV16 PsV (MOI = 2.0) for 72 h (Figures 2G and S5B). Similar re-
sults were observed in YAP1 differentially expressed ECT1 cells
and SiHa cells (Figures 2H, 2I, S5C, and S5D). These results pro-
vide direct evidence that hyperactivation of YAP1 increases the
susceptibility of cervical epithelial cells to HPV infection.
YAP1 Facilitates HPV Infection of hCerEC Cells by
Upregulating the Putative HPV Receptors
The specificity and susceptibility of a host cell to viral infection
are controlled by the interaction between virus and the putative
viral receptor molecules on the host cell membrane (Grove and
Marsh, 2011). Heparan sulfate proteoglycans (HSPGs; such as
Syndecan-1), integrin a6 (ITGA6), and epidermal growth factor
receptor (EGFR) have been identified as putative HPV receptor
molecules (Raff et al., 2013; Surviladze et al., 2012; Yoon et al.,
2001). Interestingly, we found that all examined putative HPV
receptor molecules were significantly upregulated in YAP1
hyperactivated hCerECs but downregulated in YAP1-knock-
down hCerECs (Figures 3A and 3B). Knockdown of ITGA6 in
hCerEC-YAP and hCerEC-YAPS127A cells blocked YAP- and
YAPS127A-induced increase of HPV16 PsV intake (indicated by
GFP signal) in these cells after incubation with HPV16 PsV
(MOI = 1.0) for 72 h (Figures 3C and S5E). Similarly, knockdown
of ITGA6 in SiHa cervical cancer cells also inhibited the
efficiency of HPV16 PsV infection (MOI = 1.0) (Figure S5F).
Importantly, we found that hyperactivation of YAP1 also upregu-
lated expression of ITGA6, SDC1, and EGFR in vivo (Figures 3D,
S4, and S6). IHC analyses showed that expression of ITGA6 and
SDC1 in the epithelium of the KRT14-YAPS127A mice is signifi-
cantly increased compared with that of the KRT14-rtTA control
mice (Figure S6). These results demonstrate that hyperactivation
of YAP1 upregulates the expression of the putative HPV recep-
tors on the membrane of cervical epithelial cells to facilitates
HPV infection.
Hyperactivation of YAP1 Interrupts Type I Interferon
Production in Cervical Epithelial Cells
Under normal conditions, HPV infection is thought to be cleared
up by the immune system. However, under certain pathological
conditions, host cell immunity may be compromised, and HPV
escapes immune surveillance, leading to establishment of
persistent infection and increased risk for cervical cancer in these
patients. The innate immune system constitutes the first line of
defense against HPV infection (Amador-Molina et al., 2013).
Fluorescent immunocytochemistry in the wound healing model
showed that IRF3, one of the major transcription factors control-
ling production of type I interferons (Figure S7A), is negatively
associated with YAP1 activity (Figure 4A). In non-wound areas
of the wound-healing assay, inactive YAP1 was mainly localized
to cytoplasm of hCerECs, while IRF3 was localized mainly to
nuclei (Figure 4A). However, in the ‘‘wound’’ area, YAP1 was pre-
dominantly translocated to nuclei (activated), while IRF3 was
localized predominantly to cytoplasm (inactive form; Figure 4A).
These results suggest that YAP1 may manipulate IRF3 activity
to modulate innate immunity in cervical epithelial cells.
(B) Representative images showing the expression of YAP1 (red) in mouse and human normal cervical tissues. Note that YAP1 is expressed mainly in basal cells
(arrow and arrowhead) and localized predominantly to the nuclei of these cells in cervical epithelium. Scale bar: 100 mm.
(C) Representative images showing cellular localization of YAP1 protein (green) in hCerECs during wound healing. In vitro wound-healing assay showed that in
confluent area, YAP1 was localized predominantly in the cytoplasm of hCerECs, while in the ‘‘wound’’ area, YAP1 translocated into the nuclei of these cells.
Scale bar: 20 mm.
(D) Representative images showing that HPV preferentially infected hCerECs in ‘‘wound’’ area. hCerECs were incubated in growth media with HPV16 pseu-
dovirions (PsVs; MOI = 2) for 72 h. The infection efficiency of HPV16 PsV in hCerECs is represented by the ratio of GFP-positive cells. Note that the positivity and
intensity of GFP signal were localized predominantly to cells in ‘‘wound healing’’ area. Scale bar: 100 mm.
(E) Quantification results of (D). Each bar represents mean ± SEM (n = 5). ***p < 0.001.
(F) Representative images showing HPV16 PsV-derivedGFP signal in hCerEC-MX cells (hCerECs transfectedwith an empty vector as control), hCerEC-YAP cells
(hCerECs transfected with a vector expressing wild-type YAP1), and hCerEC-YAPS127A cells (hCerECs transfected with a vector expressing YAPS127A, a
constitutively active form of YAP1). Cells were incubated in the growth media with or without HPV16 PsV (MOI = 1) for 72 h. Scale bar: 100 mm.
(G) Representative images showing HPV16 PsV-derived GFP signal in hCerEC-CTRL cells (hCerECs transfected with non-targeting scrambled short
interfering RNA [siRNA] as control) and hCerEC-siYAP cells (hCerECs transfected with YAP1-specific siRNA). Cells were incubated in growth media with HPV16
PsV (MOI = 1) for 72 h. Scale bar: 100 mm.
(H) Representative images showing HPV16 PsV-derived GFP signal in Ect1-MX, Ect1-YAP, and Ect1-YAPS127A cells. Ect1 cells is an immortalized cervical
epithelial cell line. Scale bar: 100 mm.
(I) Representative images showing HPV16 PsV-derived GFP signal in SiHa-CTRL and SiHa-siYAP cells. SiHa is a cervical cancer cell line. Scale bar: 100 mm.
Quantitative data are presented in Figure S5.
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Figure 3. Hyperactivation of YAP1 Upregulates Expression of the Putative HPV Receptor Molecules In Vitro and In Vivo
(A) RT-PCR analyses showing relative expression levels of the putative HPV receptors, including ITGA6, SDC1, and EGFR, in hCerEC-MX and hCerEC-YAPS127A
cells. Each bar represents mean ± SEM (n = 4). *p < 0.05, **p < 0.01, and ***p < 0.001.
(B) RT-PCR analyses showing expression of ITGA6, SDC1, and EGFR in SiHa-CTRL and SiHa-siYAP cells. Each bar represents mean ± SEM (n = 4). *p < 0.05,
**p < 0.01, and ***p < 0.001.
(C) Representative images showing HPV16 PsV-derivedGFP signal in hCerEC-MX, hCerEC-YAP, and hCerEC-YAPS127A cells with (siITGA6) or without (siControl)
knockdown of ITGA6 protein. Scale bar: 100 mm.
(D) Representative images showing expressions of YAP1 and thewell-studied putativeHPV receptormolecule ITGA6, in cervical tissues derived from10-month-old
control (KRT-rtTA mice) and KRT14-YAPS127A transgenic mice. Protein expression was determined using peroxidase-based immunohistochemistry. The nuclei
were counterstained with hematoxylin. Note upregulation of ITGA6 protein in the epithelium of KRT14-YAPS127A transgenic mice. Scale bar: 200 mm.
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Following viral entry, the first step in activating an innate im-
mune response against viral infection is the detection of viral
pathogens, which is mediated by the interaction between
pattern recognition receptors (PPRs) of host cells and the path-
ogen-associated molecular patterns (PAMPs) of HPV virions
(Stanley, 2012). Our RT-PCR results suggested that mRNA
expression of the well-studied PRRs for HPV, Toll-like receptors
(TLRs) TLR2 (Alphs et al., 2008) and TLR4 (Pannone et al., 2016),
was significantly downregulated in YAPS127A-expressing cells
(Figure 4B). The signal transduction from TLRs to downstream
kinase cascades requires the mediation of several adaptor pro-
teins, includingmyeloid differentiation primary response gene 88
(MYD88) and TIR-domain-containing adaptor-inducing inter-
feron-b (TRIF) (Tartey and Takeuchi, 2017). The expression of
MYD88 and TRIFmRNA was also inhibited by YAPS127A in hCer-
ECs (Figure 4C). Western blot analysis further confirmed the
downregulation of TLR2 and TRIF in hCerECs overexpressing
YAP1 (Figure S8A). These results indicated that hyperactivation
of YAP1 can negatively regulate the viral recognition pathway.
The recognition of HPV PAMPs by PRRs may trigger a series
of kinase cascades that subsequently leads to activation and
nuclear translocation of IRF1, IRF3, IRF7, and NFkB, which
are transcription factors regulating expression of type I inter-
ferons (IFNa and IFNb) and cytokines, the key molecules for anti-
viral immune response (McNab et al., 2015; Takeuchi and Akira,
2009). Similar to TLRs in hCerEC-YAPS127A cells, expression of
IRF1 and IRF7 genes was also significantly decreased in
YAP1- hyperactivated cells (Figure 4D). Consistently, knock-
down of YAP1 in these cells significantly increased expression
of IRF1 and IRF7 mRNA levels (Figure 4E). Although the level
of IRF3 protein was not significantly affected by YAP1 expres-
sion, the level of phospho-IRF3 (active form) was decreased in
hCerECs expressing YAPS127A (Figure S8A). Immunofluorescent
analysis also showed that ectopic expression of YAP1 or
YAPS127A resulted in translocation of IRF3 and NFkB1 from
nucleus to cytoplasm in hCerECs, suggesting the transcriptional
activity of IRF3 and NFkB1 was inhibited in YAP- and YAPS127A-
overexpressed cells (Figures 4F, S8A, and S8B).
Consistent with in vitro results, critical genes involved in viral
recognition signaling, such as TLR2, MYD88, and TBK1, were
significantly downregulated in KRT14-YAPS127A mice (Fig-
ure 4G). IHC staining results further demonstrated that in com-
parison with the control cervical tissues, the cervical epithelial
layer of KRT14-YAPS127A mice expressed significantly lower
levels of MYD88 and TBK1 (Figures 4H and S8C), suggesting
that hyperactivation of YAP1 attenuates the innate immune
system in vivo.
Hyperactivation of YAP1 Interrupts the IFNRs-JAKs-
STATs Signaling Pathway to Inhibit Production of
Antiviral ISGs in Cervical Epithelial Cells
Normally, the secreted IFNs bind to IFN receptors on adjacent
cells, resulting in the activation of the JAK-STAT pathway in
these cells (Figure S7B). Phosphorylated STAT1 and STAT2
then bind with IRF9 to form a complex called IFN-stimulated
gene factor 3 (ISGF3) to initiate the transcription of hundreds of
genes that act to block viral infection (Schneider et al., 2014).
The RT-PCR results showed that mRNA expressions of IFNa re-
ceptor 2 (IFNAR2), JAK1, JAK2, STAT1, and IRF9 were downre-
gulated in hCerEC-YAPS127A cells (Figures 5A and Figure S9A),
while mRNA expression of IFNAR1 and IRF9 was upregulated
in YAP1-knockdown hCerECs (Figure 5B). Immunoblotting
analysis also detected reduced levels of JAK1, STAT1, phos-
pho-STAT1, and IRF9 proteins in YAP-overexpressed cells
(Figure 5C). These results indicated that hyper-active YAP1
could inhibit the signal transduction from type I IFNs to ISGF3.
Consistent with this, immunofluorescence confocal microscopy
showed that compared with control (MX) cells, ectopic expres-
sion of YAP1 or YAPS127A not only reduced the signal intensity
of total STAT1 and IRF9 but also decreased the immunosignal
of nuclear STAT1 and IRF9. Treatment of hCerECs with recom-
binant IFNa2b (50 IU, 45 min) rapidly induced nuclear accumula-
tion of STAT1 and IRF9 in hCerEC-MX cells, but it failed to do so
in hCerEC-YAP and hCerEC-YAPS127A cells (Figure S9B). We
also noticed that in control cells, IRF9 and STAT1 formed multi-
ple foci in the nucleus. However, the focal pattern of IRF9 and
STAT1wasdiminished inYAPS127A-expressedcells (FigureS9B),
indicating that the transcriptional activity of ISGF3 complex was
inhibited by YAP1 hyperactivation. Similar results were observed
in wound-healing assay (Figure S10).
Type I interferons (mainly IFNa and IFNb) can induce expres-
sions of a large spectrum of interferon-stimulated genes (ISGs)
in virus-infected cells as well as neighbor cells. IFN-induced
ISGs are involved in almost all key steps of antiviral effects in
host cells, including inhibition of virus entry, blockade of virus
replication, and obstruction of viral egress (Schneider et al.,
Figure 4. Hyperactivation of YAP1 in Cervical Epithelial Cells Inactivates Signaling Pathways Involved in Type I Interferon Production In Vitro
and In Vivo
(A) Representative images from in vitro experiments showing expression and location of YAP1 and IRF3 in normal and ‘‘wound’’ area of cultured hCerECs.
YAP1 and IRF3 proteins were visualized using an Alexa 488 (green)-conjugated secondary antibody. Nuclei were stained with DAPI (blue). Scale bar, 20 mm.
(B and C) Quantitative data showing mRNA levels of TLR2 and TLR4 (B), and their adapter proteins MYD88 and TRIF (C) in hCerEC-MX (control) and hCerEC-
YAPS127A cells. Each bar represents mean ± SEM (n = 4). **p < 0.01 and ***p < 0.001.
(D and E) Quantitative data showing mRNA levels of IRF1 and IRF7 in hCerEC-MX (control) and hCerEC-YAPS127A cells (D) and in control (CTRL) and YAP1-
knockdown hCerECs (siYAP) (E). Each bar represents the mean ± SEM (n = 4). **p < 0.01 and ***p < 0.001.
(F) Representative images showing the expression and location of YAP1 and IRF3 in hCerEC-MX (control), hCerEC-YAP, and hCerEC-YAPS127A cells. YAP1 and
IRF3 proteins were visualized using an Alexa 488 (green)-conjugated secondary antibody. Nuclei were stained with DAPI (blue). Scale bar, 20 mm.
(G) RT-PCR analyses showing expressions of YAP1, TLR2, MYD88, and TBK1 mRNA in cervical tissues from KRT14-rtTA control (CTRL) and KRT14-YAPS127A
mice. Each bar represents the mean ± SEM (n = 4). **p < 0.01 and ***p < 0.001.
(H) Representative images showing expression of YAP1, MYD88, and TBK1 proteins in cervical tissues from KRT14-rtTA control (CTRL) and KRT14-YAPS127A
mice. Protein expression was determined using peroxidase-based immunohistochemistry. The nuclei were counterstained with hematoxylin. Note upregulation
of YAP1 and downregulation of MYD88 and TBK1 proteins in the epithelium of KRT14-YAPS127A transgenic mice. Scale bar: 250 mm.
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Figure 5. Hyperactivation of YAP1 Suppresses the IFNs/JAKs/STATs Pathway in Cervical Epithelial Cells
(A) Quantitative experiments showing mRNA levels of major components of the IFNRs/JAK/STAT/IRF9 pathway and downstream target genes in control
(hCerEC-Mx) and hCerEC-YAPS127A cells. Each bar represents the mean ± SEM (n = 4). *p < 0.05, **p < 0.01, and ***p < 0.001.
(legend continued on next page)
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2014). As expected, expression of genes encoding ISGs that
directly inhibit virus infection, such as MX1 (myxovirus resis-
tance 1), ISG15, APOBEC3G (apolipoprotein B mRNA editing
enzyme, catalytic polypeptide-like 3G), OAS1 (20-50-oligoadeny-
late synthetase 1), TRIM5 (tripartite motif family protein 5), and
IFI44L, was significantly downregulated in YAPS127A-expressed
hCerECs (Figures 5A and S9A). Consistently, knockdown of
YAP1 in hCerECs upregulated many antiviral ISGs, such as
MX1, CH25H, IFITMs (inhibitors of virus entry), and APOBEC3G,
OAS1/2, ISG15, and IFI44L (suppressors of virus translation and
replication) (Figures 5B and S11A). Taken together, these results
provide strong evidence that constitutive activation of YAP1 can
suppress the IFNaRs-JAKs-STATs pathway and reduce the
production of antiviral ISGs.
To further examine the role of hyperactivated YAP1 on the IFN-
induced antiviral effect, we pretreated control and YAP-overex-
pressing hCerECs with recombinant IFNa2b (50 IU) for 24 h and
then incubated these cells with HPV16 PsVs (MOI = 1.0) for 72 h.
IFNa2b treatment resulted in a significant decrease in the num-
ber of GFP-positive cells in control hCerECs (Figures 5D and
S11B). However, IFNa2b had no effect on the positivity and in-
tensity of GFP signal in hCerEC-YAP and hCerEC-YAPS127A cells
(Figures 5D and S11B). These results, combined with the above
data, suggested that hyperactivation of YAP1 in cervical epithe-
lial cells not only suppresses the production of type I IFNs but
may also diminish the antiviral effects of IFNs.
Consistent with in vitro results, expression of genes encoding
the core components of the JAK-STAT/IRF9 pathway, such as
JAK1, STAT1, and IRF9, were also significantly reduced in
KRT14-YAPS127A mice (Figure 5E). IHC staining results further
demonstrated that in comparison with the control cervical tis-
sues, cervical epithelial layer of KRT14-YAPS127Amice expressed
significantly lower levels of JAK1 and IRF9 proteins (Figures 5F
and S11C). MX1 and ISG15, the two best characterized antiviral
ISGs, were diminished at both transcriptional (mRNA) and protein
levels in KRT14-YAPS127Amice (Figures 5E, 5F, andS11C). These
results provide evidence that hyperactivation of YAP1 attenuates
the innate immune system in vivo.
HPV Synergizes with YAP1 to Promote Carcinogenesis
of Cervical Epithelium In Vivo
Although hyperactivation of YAP1 is sufficient to induce develop-
ment of cervical cancer, it generally took 6–8 months to observe
invasive cancer in the cervical epithelium under constitutive in-
duction of YAP1 expression with low concentration of Dox.
The observation that hyperactivation of YAP1 induced expres-
sion of the putative HPV receptors and suppression of innate im-
mune system in cervical epithelial cells indicates that HPV and
YAP1 might function in a synergic manner to drive the develop-
ment of cervical cancer. To examine the potential synergism of
hyperactivated YAP1 and HPV oncoproteins, we used KRT14-
E6 (HPV16) mice, KRT14-E7 (HPV16) mice (Riley et al., 2003),
and KRT14-YAPS127A mice to create two new transgene mouse
models, KRT14-E6-YAPS127A and KRT14-E7-YAPS127A mice
(Figures 6A and 6B). These mice express both HPV oncoprotein
E6 (or E7) (under control of KRT14 promoter) and YAPS127A (un-
der control of KRT14 and Dox induction) in cervical epithelial
cells. Consistent with previous reports (Riley et al., 2003),
KRT14-E6 and KRT-E7 mice rarely developed cervical cancer
without exposure to a relatively high concentration of estrogen,
even after treatment with a low concentration of Dox for
1.5 years. Most KRT14-YAPS127A mice, as shown before, devel-
oped cervical cancer after 6–8 months of Dox induction.
However, we found that most of KRT14-E6-YAPS127A and
KRT14-E7-YAPS127A mice developed invasive cervical cancer
within 4 months of induction (Figure 6C). Compared with
KRT14-YAPS127A mice, cancer progression in KRT14-E6-
YAPS127A and KRT14-E7-YAPS127A mice was much faster than
that in KRT14-YAPS127A mice. After induction with a low concen-
tration of Dox for 9 months, about 30% of KRT14-YAPS127A mice
were dead (or euthanized because of urethral obstruction).
However, the death rate in KRT14-E6-YAPS127A and KRT14-
E7-YAPS127A mice reached 60% and 75%, respectively (Figures
6D and 6E). Cancer cells in the cervical tissue of KRT14-E6/E7-
YAPS127A mice were more invasive and aggressive than in
KRT14-YAPS127A mice (Figure 6C). These in vivo data strongly
support our hypothesis that HPV synergizes with hyperactivated
YAP1 to drive initiation and progression of cervical cancer.
DISCUSSION
Novel Mouse Models Suggest that HPV Is Not a
Necessary Cause of Cervical Cancer
The recognition of HPV infection as amajor risk factor for cervical
cancer has been considered a breakthrough in cancer research
in the past three decades. During the 1990s, epidemiological
studies, supported by molecular technologies, concluded that
persistent high-risk HPV (hrHPV) infection was a necessary
cause of cervical cancer, implying that cervical cancer does
not and will not form in the absence of persistent HPV infection
(B) Quantitative data showing mRNA levels of YAP1 and genes of the core components of the IFNR/JAK/STAT antiviral pathway in hCerEC-CTRL cells (cells
transfected with scrambled non-target siRNA) and hCerEC-siYAP cells (cells transfected with YAP1-specific siRNA). Each bar represents themean ±SEM (n = 4).
*p < 0.05, **p < 0.01, and ***p < 0.001.
(C) Representative blots from three independent experiments showing expression and activation of key proteins and kinases in the JAK/STAT/IRF9 pathway in
hCerEC-MX (control), hCerEC-YAP, and hCerEC-YAPS127A cells.
(D) Representative images showing HPV16 PsV-derived GFP signal in hCerEC-MX, hCerEC-YAP, and hCerEC-YAPS127A cells in the presence or absence of
recombined human interferon alpha 2b (IFNa2b). GFP signal indicates the infection efficiency of HPV16 PsV in these cells. Scale bar: 100 mm. Quantitative results
of GFP signal is presented in Figure S11B.
(E) RT-PCR analyses showing expression of JAK1, IRF9, STAT1, andMX1mRNA in cervical tissues from control KRT14-rtTA (CTRL) and KRT14-YAPS127A mice.
Each bar represents the mean + SEM (n = 4). ***p < 0.001.
(F) Representative images showing expression of JAK1, IRF9, MX1, and ISG15 proteins in cervical tissues from KRT14-rtTA control (CTRL) and KRT14-YAPS127A
mice. Protein expression was determined using the peroxidase-based immunohistochemistry. The nuclei were counterstained with hematoxylin. Scale bar:
250 mm.
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Figure 6. HPV Oncoproteins Accelerate Cervical Cancer Initiation and Progression in KRT14-YAPS127A Transgenic Mice
(A) A schematic diagram showing the mating strategy for generating of KRT14-E6-YAPS127A and KRT14-E7-YAPS127A transgenic mice.
(B) Representative images showing PCR products of transgenes (genotyping results) in tissues extracted from wild-type (lane 2), KRT14-YAPS127A (lanes 3 and
8), KRT14-E6 (lane 4), KRT14-E6-YAPS127A (lane 1), KRT14-E7 (lanes 5 and 7), and KRT14-E7-YAPS127A (lane 6) transgenic mice.
(legend continued on next page)
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(Schiffman and Castle, 2003; Walboomers et al., 1999).
However, although the estimated lifetime risk for HPV infection
can be 75% (Koutsky, 1997), the lifetime risk for developing
cervical cancer is only 0.68% (Howlader et al., 2012). More-
over, cervical cancer occurs many years after HPV infection
(Howlader et al., 2012; Weaver, 2006). In addition, cervical can-
cer shows very high intratumor heterogeneity (Cancer Genome
Atlas Research Network et al., 2017; Lyng et al., 2004). These
observations indicate that exposure to HPV alone is insufficient
for cervical cancer development (Perez-Plasencia et al., 2008;
Uren et al., 2005). Animal studies showed that cervical epithelial
specific expression of HPV16 E6, E7, or their combination did not
induce cervical cancer without support of exogenous estrogen
(Brake and Lambert, 2005; Riley et al., 2003). Accumulating
evidence suggests that the presence of a persistent hrHPV
infection risk is not sufficient to immortalize and transform the
epithelial cells of the host (Gatza et al., 2005; Roden and Wu,
2006). Currently, it is widely accepted that that persistent HPV
infection is a necessary but insufficient cause for the carcinogen-
esis of cervical epithelium (National Cancer Institute, 2018).
Existing evidence indicates that the presence of genetic and
epigenetic alterations is necessary for the carcinogenesis of
cervix, although the specific alteration or alterations are still not
clear. In the present study, we provide in vitro and in vivo evi-
dence to show that pathological alterations of the Hippo/YAP
signaling pathway are sufficient to induce cervical cancer,
regardless HPV infection. However, the synergism between
HPV oncoprotein and YAP1 oncogene significantly accelerates
tumorigenesis of the cervix.
Central Role and Functional Mechanism of YAP1 in
Cervical Cancer Development
The role of the Hippo/YAP1 signaling pathway in cancer devel-
opment has been intensively studied over the past 10 years
(Mo et al., 2014; Pan, 2010; Yu et al., 2015; Zanconato et al.,
2016). Both in vitro and in vivo evidence indicates that dysregu-
lation of the Hippo signaling cascade and activation of proto-
oncogene YAP1 are linked to many human cancers, including
cancers of the skin, lung, colon, breast, kidney, liver, and ovary
(Gomez et al., 2014; He et al., 2015a; Lee et al., 2010; Steinhardt
et al., 2008). Cross-cancer genomic analyses based on TCGA
datasets showed that the most frequent genomic alteration of
the Hippo/YAP1 pathway occurs in the cervical carcinoma.
This observation is supported by recent genome-wide screening
by TCGA, which also showed that the copy number of genes in
chromosome 11q22 was frequently amplified in CVSCC. Inter-
estingly, YAP1 and its downstream target genes BACR2 and
BACR3 are located in this area (Cancer Genome Atlas Research
Network et al., 2017). On the basis of DNA methylation status,
the authors identified a sub-group of cervical cancer that had
epithelial–mesenchymal transition (EMT) features and was
associated with the worst survival outcomes. Importantly, they
found that YAP1 gene was amplified in cancer cells derived
from the EMT cluster, and YAP1 protein was the most signifi-
cantly differentially expressed protein that distinguished the
EMT cluster from other sub-groups (Cancer Genome Atlas
Research Network et al., 2017). Wemined TCGA cervical cancer
datasets and found that besides YAP1 amplification, the up-
stream genes of the Hippo pathway, including MST1, LATS1/2,
and FAT1/2/3/4, which negatively regulate YAP1 activity, were
frequently deleted and/or mutated in cervical cancer patient
samples. Our previous data also showed that hyperactivation
of YAP1 in hCerECs induced malignant transformation of these
cells (He et al., 2015b). The development of CVSCC in KRT14-
YAPS127A mice, which are HPV negative, strongly supports the
notion that the disrupted Hippo pathway and the subsequent
hyperactivation of YAP1 represent a novel mechanism of cervi-
cal carcinogenesis.
The precisemechanism for the Hippo/YAP pathway regulating
cervical cancer cell growth remains largely undefined. Our recent
study demonstrated that overexpression of YAP1 in cervical
cancer cells can overcome the contact inhibition-induced cell
growth inhibition, promote cell cycle progression, and signifi-
cantly stimulate cervical cancer cell growth in vitro and in vivo
(He et al., 2015b). Knockdown of YAP1-negative regulators
LATS1/2 resulted in a significant increase in the cervical epithe-
lial cell proliferation. Moreover, we found that the EGFR pathway
was involved in YAP1-induced cervical cancer cell proliferation
and migration. Activation of YAP1 in cervical cancer cells signif-
icantly stimulated the expression of EGFR and its ligands TGFa
and AREG. In turn, TGFa and AREG, via EGFR signaling, sup-
pressed the Hippo pathway and activated YAP protein (dephos-
phorylated LATS1,MOB1, and YAP1) to promote cervical cancer
cell growth (He et al., 2015b). The existence of this Hippo/YAP
and EGFR feedback loop in human cervical cancer suggested
that the combined targeting of the Hippo/YAP and EGFR path-
ways may be an efficient way to treat cervical cancer.
Previous studies showed that HPV infection is a necessary
cause of cervical cancer. In reality, following infection, themajor-
ity of HPV becomes undetectable within 1–2 years, and the virus
is cleared spontaneously by the immune system. Nevertheless,
persistent HPV infection happens in some high-risk individuals
and increases the risk for cervical cancer in these women. The
mechanism by which HPV evades immune surveillance in these
patient is not clear. Some reports suggest that HPV modifies the
innate immune system in the host cells, leading to the failure of
virus clearance and persistent HPV infection (Scott et al., 2001;
Westrich et al., 2017). However, this modification requires HPV
(C) Representative images showing histology of cervical tissues (H&E staining) collected from control, KRT14-E6/E7, KRT14-YAPS127A, KRT14-E6-YAPS127A, and
KRT14-E7-YAPS127A mice after induction of YAPS127A gene expression with doxycycline in drinking water for 4–5 months.
(D) Kaplan-Meier survival curves showing the overall survival rates of control mice (control, n = 12), KRT-14-YAPS127A mice (YAPS127A, n = 14), KRT14-E6 mice
(E6, n = 13), and KRT14-E6-YAPS127A mice (E6+YAPS127A, n = 12) after inducing expression of transgenes with 0.05 mg/mL doxycycline (in drinking water).
(E) Kaplan–Meier survival curves showing the overall survival rates of control mice (control, n = 9), KRT-14-YAPS127A mice (YAPS127A, n = 14), KRT14-E7 mice
(E7, n = 7), and KRT14-E7-YAPS127A mice (E7+ YAPS127A, n = 8) after inducing expression of transgenes with 0.05 mg/mL doxycycline (in drinking water).
(F) A schematic diagram showing the proposed mechanism by which hyperactivated YAP1 and high-risk HPVs synergize to drive the initiation and progression of
cervical cancer.
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E6 and E7 oncogene expression, which happens after HPV initial
infection. Therefore, unknown alterations in the defense system
of the vulnerable individuals may contribute to the establishment
of the persistent HPV infection. In the present study, we found
that hyperactivation of YAP1 may be a major contributor to the
HPV persistent infection. First of all, results in the present study
showed that hyperactivated YAP1 upregulated putative HPV re-
ceptor molecules such as ITGRA6, SDC1, and EGFR, which may
facilitate the HPV entry process during early stage of HPV infec-
tion. Second, we found that hyperactivation of YAP1 in cervical
epithelial cells downregulated key components of viral recogni-
tion by the innate immune system. We observed that TLR2 and
TLR4, well-studied PRRs, as well as their adaptor proteins
MYD88 and TRIF, were inhibited, which could exacerbate HPV
infection. Third, we found that ectopic expression of YAPS127A in-
hibited the expression and activation of transcriptional factors
that are critical for the production of type I IFNs, including
IRF1, IRF3, and IRF7, resulting in decreases of IFNA1, IFNB1,
and IFNE in hCerECs. These IFNs can activate intracellular anti-
viral programs and play a key role in the development of
innate and adaptive immune responses. Finally, we observed
that the expression and activation of key components of the
type I IFN pathway, including IFNAR2, JAK1, STAT1, and IRF9,
were broadly inhibited by expression of YAPS127A in cervical
epithelial cells. Inhibition the IFNAR2/JAK1/STAT1 signaling
pathway resulted in massive downregulation of antiviral ISGs,
including MX1, CH25H, and IFITMs (inhibitors of virus entry)
and APOBEC3G,OAS1, ISG15, and IFI44L (suppressors of virus
translation and replication). More important, the inhibition of
innate antiviral pathways by YAP was confirmed in studies with
the K14-YAPS127A transgenic mouse. Therefore, the present
studies indicate that disruption of the Hippo pathway and subse-
quent activation of YAP1 in the cervical epithelial may result in
defective innate antiviral immunity, which may allow HPV to
escape immune surveillance, leading to persistent HPV infec-
tion. Consistent with this observation, two research groups in
China recently reported that YAP1 negatively regulated the
production of type I interferon by suppressing TBK1 activity
(Zhang et al., 2017; Wang et al., 2017). In the Drosophila model,
hyperactivation of Yorkie (YAP in mammals) also led to the
decrease of antimicrobial peptides in adipose tissues, suggest-
ing that YAP1 regulation of innate immunity is a conserved
mechanism of pathological immune suppression (Liu et al.,
2016). These data suggest that enhancing HPV infection may
represent a new mechanism for YAP1 to control cervical cancer
development.
Identification of the Hippo/YAP Pathway as a Major
Player in Cervical Cancer Development Does Not
Reduce the Importance of hrHPV in Cervical
Tumorigenesis
Although our transgenic mouse model demonstrates that HPV
infection is not a necessary event for the development of CVSCC,
our present data, plus previous numerous reports, still support
the notion that hrHPV infection, especially in vulnerable popula-
tions, greatly increases the risk for cervical cancer. Therefore,
identification of the Hippo/YAP pathway as a major player in cer-
vical carcinogenesis does not reduce the importance of hrHPV in
the development of cervical cancer. Our data clearly indicate that
hyperactivation of YAP1 increased viral infectivity and sup-
pressed innate immunity, two events that greatly increase the
susceptibility of cervical epithelial cells to HPV infection and facil-
itate the establishment of persistent HPV infection in these cells.
Although HPV alone is not sufficient to induce malignant transfor-
mation of cervical epithelial cells, expression ofHPVoncoproteins
E6 and E7 leads to inactivation of critical tumor suppressors such
as TP53 and RB1 in many types of cells (Dyson et al., 1989;
Scheffner et al., 1990; White et al., 2016). Inactivation of TP53
and RB1 can lead to extension of cell life (via suppression of
senescence) and even induce immortal phenotype in cervical
epithelial cells (Liu et al., 2018), paving the way for malignant
transformation of HPV-infected cells by an oncogenic signal
(such as hyperactivation of YAP1). Moreover, we have shown
that HPV can prevent proteinase-dependent degradation of
YAP1 protein, which maintains high levels of YAP1 protein in
HPV-infected cervical epithelial cells. Most important, we found
that HPV E6 protein suppressed Hippo pathway in the cervical
epithelial cells (He et al., 2015b). Clearly, HPV synergizes with hy-
peractivated YAP1 to drive carcinogenesis of cervix. Introduction
of HPV16 E6 and E7 oncoproteins significantly promoted cervical
carcinogenesis of KRT14-YAPS127A cells, indicating that syner-
getic function between YAP1 and HPV does exist during cervical
tumorigenesis. Therefore, the current HPV vaccination program,
which has been shown to be very effective in preventing selected
types of HPV (Baldur-Felskov et al., 2014; Sankaranarayanan,
2015), may greatly reduce infection by HPV and carcinogenesis
of the cervix in women in the near future.
In conclusion, the in vitro and in vivo results from the present
study show that YAP1, the major effector of the Hippo pathway,
plays a central role in the development of cervical cancer.
Hyperactivation of YAP1 is sufficient to induce malignant trans-
formation of cervical epithelial cells and development of
invasive cervical cancer in mouse models. Disruption of the
Hippo pathway and subsequent activation of YAP1 in cervical
epithelial cells may facilitate the establishment of persistent
HPV infection by upregulating putative HPV receptor molecules
and suppressing host cell innate immunity. Together with our
previous observations that HPV16 E6 protein is able to suppress
the Hippo pathway (thereby activating YAP1) and prevent YAP1
from proteasome-mediated degradation, we conclude that the
interaction between the Hippo/YAP pathway hrHPV is a key
player in cervical carcinogenesis. The present findings are ex-
pected to influence current cervical cancer preventive screening,
early detection, and treatment. The current HPV vaccination pro-
grammay greatly reduce infection by HPV and carcinogenesis of
the cervix in women in the near future. The novel mouse models
developed in this study provide new tools for further investiga-
tion of cervical cancer initiation and progression.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Ki67 Abcam (Cambridge, MA) ab15580
SDC1 Abcam (Cambridge, MA) ab188861
p40(deltaNp63) Ventana Medical Systems, Inc. (Tucson, AZ) 790-4950
P53 Santa Cruz Biotechnology Inc (Dallas, TX) sc-126
ISG15 Santa Cruz Biotechnology Inc (Dallas, TX) sc-166755
YAP Cell Signaling Technology Inc. (Danvers, MA) #4912
phospho-YAP (Ser127) Cell Signaling Technology Inc. (Danvers, MA) #4911
Pan KRT Cell Signaling Technology Inc. (Danvers, MA) #4545
EGFR Cell Signaling Technology Inc. (Danvers, MA) # 4267
ITGA6 Cell Signaling Technology Inc. (Danvers, MA) #3750
TLR1 Cell Signaling Technology Inc. (Danvers, MA) # 2209
TLR2 Cell Signaling Technology Inc. (Danvers, MA) #1227
MYD88 Cell Signaling Technology Inc. (Danvers, MA) #4283
TRIF Cell Signaling Technology Inc. (Danvers, MA) #4596
TBK1 Cell Signaling Technology Inc. (Danvers, MA) #3504
NF-kB1 p105/p50 Cell Signaling Technology Inc. (Danvers, MA) #12540
NF-kB2 p100/p52 Cell Signaling Technology Inc. (Danvers, MA) #3017
JAK1 Cell Signaling Technology Inc. (Danvers, MA) #3344
JAK2 Cell Signaling Technology Inc. (Danvers, MA) #3230
STAT1 Cell Signaling Technology Inc. (Danvers, MA) #9172
STAT2 Cell Signaling Technology Inc. (Danvers, MA) #72604
IRF3 Cell Signaling Technology Inc. (Danvers, MA) #11904
IRF9 Cell Signaling Technology Inc. (Danvers, MA) #76684
phospho-STAT1 Cell Signaling Technology Inc. (Danvers, MA) #7649
phospho-STAT2 Cell Signaling Technology Inc. (Danvers, MA) #88410
b-actin Sigma-Aldrich (St. Louis, MO) #A5441
Bacterial and Virus Strains
p16L1L2 Addgene #45291
pCIneoEGFP Addgene #46949
MXIV-neo Jixing Dong Lab N/A
YAP-neo Jixing Dong Lab N/A
YAPS127A-neo Jixing Dong Lab N/A
Biological Samples
The human cervical tissues microarray US Biomax, Inc BB10011
Panomics, Inc. CIN481, 482, & 483
Chemicals, Peptides, and Recombinant Proteins
Interferon alpha 2b R&D systems Inc. #11105-1
Critical Commercial Assays
RNAeasy micro kit QIAGEN #74004
iScript Reverse Transcription Supermix for RT-qPCR BIO-RAD #1708841
iTaq Universal SYBR Green Supermix BIO-RAD #1725121
VECTASTAIN Elite ABC HRP Kit (Peroxidase, Rabbit IgG) VECTOR LABORATORIES PK-6103
Antigen Unmasking Solution, Citric Acid Based VECTOR LABORATORIES H-3300
ImmPACT DAB Peroxidase (HRP) Substrate VECTOR LABORATORIES SK-4105
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to, and will be fulfilled by the Lead Contact, Cheng Wang (cwang34@
mgh.harvard.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse Model Studies
Mouse model handling and animal experimental procedures were approved by the Institutional Animal Care and Use Committee
(IACUC) of the University at Nebraska Medical Center (UNMC) and Massachusetts General Hospital (MGH). KRT14-rtTA (FVB-
Tg(KRT14-rtTA) F42Efu/J, #008099) mice were from The Jackson Laboratory. These mice express the reverse tetracycline-
controlled transactivator (rtTA) protein in basal cells of stratified epithelium under control of the human keratin 14 (KRT14) gene
promoter (Nguyen et al., 2006). The TRE-YAPS127A mice were from Dr. Fernando Camargo’s lab (Boston Children’s hospital). These
mice express a constitutively active form of YAP1 protein (YAPS127A) under the control of a tetracycline regulatory element (TRE)
(Camargo et al., 2007). The KRT14-E6 and KRT14-E7 mice, which express HPV16 E6 and HPV16 E7 protein under control of
KRT14 promoter, respectively, were from Dr. Lambert’s laboratory (Herber et al., 1996; Song et al., 1999). Mouse breeding schemes
were shown in Figures 1A and 6A. Genotyping was performed using RT-PCR technique and tail tissue. The genomic DNA in tails was
extracted using DirectPCR Lysis Reagent (#102-T) from Viagen Biotech Inc. (Los Angeles, CA). Briefly, tail tissue was lysed in a sin-
gle-tube with 250ml DirectPCR Lysis and 5ml 20mg/ml Proteinase K (Sigma, #p6556) at 55C for 24 hours followed by incubating at
85C for 1 hour. After centrifuging, clear lysate (0.75 ml) was directly used for 20 ml PCR reaction. Primers for genotyping and expected
size of each gene are listed in Table S1. Female mice were used for cervical cancer modeling. All control, KRT-14-YAPS127A, KRT14-
E6/E7, and KRT14-E6/E7-YAPS127A transgenic mice were treated with 0.05 mg/mL Dox in drinking water (long-term treatment)
or 2 mg/mL Dox in drinking water (2-week short-term treatment) to induce the expression of transgenes when they were
three months old. Mice were euthanized and recorded as dead if they showed serious illnesses (dysuria, wasting, or sluggishness)
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
ImmPACT NovaRED Peroxidase (HRP) Substrate VECTOR LABORATORIES SK-4805
VECTASTAIN ABC-AP Staining KIT (Alkaline
Phosphatase, Rabbit IgG)
VECTOR LABORATORIES AK-5001
BLOXALL Endogenous Peroxidase and Alkaline
Phosphatase Blocking Solution
VECTOR LABORATORIES SP-6000
VECTOR Red Alkaline Phosphatase (Red AP)
Substrate Kit
VECTOR LABORATORIES SK-5100
Experimental Models: Cell Lines
Primary hCerECs ScienCell Research Laboratories #7060
Ect1/E6E7 cells ATCC CRL-2614
SiHa ATCC HTB-35
Experimental Models: Organisms/Strains
KRT14-rtTA Mice (FVB-Tg(KRT14-rtTA) F42Efu/J) The Jackson Laboratory #008099
TRE-YAPS127A mice Dr. Fernando Camargo’s lab N/A
KRT14-E6 mice Dr. Lambert’s laboratory (Herber et al.,
1996; Song et al., 1999)
N/A
KRT14-E7 mice Dr. Lambert’s laboratory (Herber et al.,
1996; Song et al., 1999)
N/A
Oligonucleotides
Primers for qRT-PCR, see Table S1 This Paper N/A
Primers for genotyping, see Table S1 This Paper N/A
siRNA (smart pool) targeting YAP1 Dharmacon M-012200-00-0005
siRNA (#1) targeting YAP1 Dharmacon D-012200-01-0002
siRNA (#2) targeting YAP1 Dharmacon D-012200-02-0002
siRNA (smart pool) targeting ITGA6 Dharmacon D-007214-01-0005
siRNA (#1) targeting ITGA6 Dharmacon D-007214-01-0002
siRNA (#2) targeting ITGA6 Dharmacon D-007214-02-0002
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and incurable. Euthanasia was recommended by an experienced veterinarian in the animal core facility if tumor-carrying mice were
incurable and suffering more than moderate stress. Mouse tissues were collected and processed for preparation of protein, RNA,
frozen and paraffin sections after euthanasia.
Cell Culture
Primary hCerECs (hCerEC, #7060) were purchased from ScienCell Research Laboratories, Inc. (Carlsbad, CA). The ectocervical
Ect1/E6E7 cells (ECT, #CRL-2614) and SiHa cervical cancer cell line (SiHa, #HTB-35) were from ATCC (Manassas, VA). Cells
were cultured according to instructions provided by ScienCell Research Laboratory and ATCC. All cell lines were validated by
short tandem repeat (STR) polymorphism analysis performed by the Genetica DNA Laboratories (Burlington, NC, USA). All cells
were maintained in a humidified atmosphere at 37C and 5% CO2.
Human Cervical Tissue Microarray
The human cervical tissues microarray (with normal control, CINs and cancerous tissues with stage and grade information) was
purchased from US Biomax (Rockville, MD) and Panomics Inc (Richmond, CA). The use of archived human tissue was approved
by Institutional Review Board (IRB) of University of Nebraska Medical Center.
METHOD DETAILS
Reagents and Materials
Interferon alpha 2b (IFNa2b, #11105-1) was purchased from R&D systems Inc. (Minneapolis, MN). DMEM/F12 culture media
(#SH-300-2301LR) were from Fisher Scientific. Ultroser Serum Substitute (#15950-017) was purchased from Pall Corporation
(Port Washington, NY). iScript Reverse Transcription Supermix (#1708841) and iTaq Universal SYBR Green Supermix
(#1725121) were purchased from Bio-Rad Laboratories, Inc. (Hercules, CA); RNeasy Mini Kit (#74106) was purchased from
QIAGEN Inc. (Valencia, CA). YAP siRNAs and ITGA6 siRNAs were purchased from Dhamarcon/Thermo Scientific (Pittsburgh, PA).
The SuperSignal West Femto Chemiluminescent Substrate Kit (#34095) for western blotting was from Pierce/Thermo Scientific
(Rockford, IL); PVDF transfer membrane (IPVH00010) was from Merck Millipore Ltd (Darmstadt, Germany). Other General Chemical
Reagents were purchased from Sigma (St. Louis, MO), Fisher (Pittsburgh, PA), or United States Biochemical (Cleveland, OH). Infor-
mation of antibodies (antibody name, catalog numbers, and sources) used in this study is listed in key resources table.
IHC
Expression of YAP1 (in Figures 1, 2, S2, and S4), Ki67, deltaNp63, p16INK4A, Pan KRT, EGFR, P53, YAP1, ITGA6, and SDC1 in
human or/and mouse cervical tissues were detected using peroxidase-based IHC kits (VECTASTAIN ELITE ABC KITS, #PK-6101
for Ribbit IgG, #PK-6102 for Mouse IgG, Vector Laboratories, Burlingame, CA]. Mouse cervical tissues were deparaffinized with
xylene and then rehydrated with gradient ethanol in ddH2O. Antigens were retrieved at 115
C with a pressure cooker for 20 minutes
using Citrate-based 1% unmasking solution (H-3300, Vector Laboratories, Burlingame, CA). Endogenous peroxidase activity was
quenched with 1% hydrogen peroxide for 30 minutes. Slides were incubated with blocking buffer for 30 minutes before incubating
with primary antibodies at 4C for 16 hours. After washing with PBST for 33 5 minutes, slides were incubated with Biotinylated sec-
ondary antibody (provided in the Kit) at 22C for 45 minutes. Antigens were visualized with VECTASTAIN ELITE ABC kits ((#PK-6101
for Ribbit IgG, #PK-6102 for Mouse IgG) and ImmPACT DAB kit (#SK4105, Vector Laboratories, Burlingame, CA) / ImmPACT
NovaRED substrate kit (#AK-4800) (Vector Laboratories, Burlingame, CA) according to instructions provided in kits. The sections
were also counterstained with hematoxylin (#H-3401, Vector Laboratories, Burlingame, CA) for 30 seconds to visualize nuclei.
Expression of YAP1 in mouse cervical tissues showed in Figure 2B was detected by alkaline phosphatase-based detection
systems using VECTASTAIN ABC-AP Staining Kit (Rabbit IgG, # AK-5001). The basic experimental steps of ABC-AP kit are similar
with ELITE ABC system, except that the endogenous enzyme activity was blocked with BLOXALL Blocking Solution (#SP-6000, Vec-
tor Laboratories) and the signal was visualized using Vector Red Substrate kit (#SK-5100) (Vector Laboratories, Burlingame, CA).
All stained sections were scanned with an iSCAN Coreo Slide Scanner (Ventana Medical Systems, Inc. Oro Valley, AZ). The signal
intensity and positivity (the ratio of positive cell number relative to the total cell number) of immunosignal on each section were
quantified using an Aperio ImageScope software (Leica Biosystems Imaging, Inc. Vista, CA).
Fluorescent Immunocytochemistry
The expression and cellular location of YAP1, IRF3, IRF9, NFKB1, and STAT1 were analyzed by fluorescent immunocytochemistry as
described previously (Lv et al., 2017). Cells were grown on coverslips in a 24-well plate. After treatment, cells were fixed with 4%
formaldehyde (in 1X PBS) at 4C for 20 minutes, rinsed with PBST for 3 times X 5 minutes, blocked cells with normal donkey serum
(10%) for 1 hour before incubating with primary antibody (200x) at 4C for 16 hours. Antigen was visualized with fluorochrome-
conjugated secondary antibodies. Fluorescence-conjugated secondary antibodies for immunofluorescent analyses, including
Alexa Fluor 488 AffiniPure Donkey Anti-Rabbit IgG (#711-545-152) and Alexa Fluor 488 AffiniPure Donkey Anti-Mouse IgG
(#715-545-150), were from the Jackson Immunoresearch Laboratories Inc. (West Grove, PA); Rhodamine Phalloidin (#R415) for
visualizing actin was from Thermo Fisher Scientific (Rockford, IL). Nuclei were stained with DAPI. Images were captured using a
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ZEISS Xradia 810 Ultra Confocal Laser Scanning Microscope and analyzed with Zeiss Zen 2012 software (Carl Zeiss Microscopy,
LLC, Thornwood, NY).
Western Blot Analysis
Western blot was used to determine the relative protein levels in cells and tissues with a protocol described previously with minor
modification (Hua et al., 2016). Cells were harvested and lysed (150ml/106 cells) on ice. Protein concentration was measured using
BCA assay kit. Thirty micrograms protein per sample was loaded onto the SDS-PAGE gel, fractioned using aBio-Rad electrophoresis
system, and then transferred from gel onto PVDF membranes. The protein containing membrane was blocked with 5% BSA for
60 minutes, incubated with primary antibodies at 4C for 16 hours and then probed with a HRP-linked secondary antibody
(#7074 for Rabbit IgG, #7076 for Mouse IgG, Cell Signaling Technology, Inc. Danvers, MA). The immunosignal was visualized with
a SuperSignal West Femto Maximum Sensitivity Substrate Kit (#34096, Thermo Fisher Scientific, Waltham, MA). Images were
captured and analyzed using a UVP gel documentation system (UVP, Upland, CA).
Quantitative Real Time-PCR
Total RNA from cultured human cells and mouse cervical tissues were extracted using TRIzol reagent (Invitrogen; Carlsbad, CA) and
QIAGEN RNeasy mini kit (#74106QIAGEN, Carlsbad, CA) following instructions provided by the manufacture. cDNA was synthesize
using an iScript Reverse Transcription Supermix for RT-qPCR Kit (Bio-Rad Laboratories, Inc.). qT-PCR was performed with the
Bio-Rad CFX96 real-time PCR system using an iTaq Universal SYBR Green Supermix Kit (Bio-Rad Laboratories, Inc.). GAPDH
and 18S were used as internal references. All primer sequences are shown in Table S1.
YAP1 Overexpression
Primary hCerECs were cultured following a protocol provided by the vendor (Catalog #7060, ScienCell Research Laboratories, Inc.).
SiHa (a human cervical cancer cell line contained HPV16) and ECT1 (a human endocervical cell line immortalized by HPV16 E6/E7)
cells were cultured with 2% Ultroser G serum substitute (Pall Corporation) in DMEM/F12 medium. hCerEC-MX and ECT1-MX cells
was generated by transfecting hCerEC and ECT1 cells with retrovirus-based empty MXIV vector (MX) as control; hCerEC-YAP and
ECT1-YAP cells were generated by transfecting hCerEC and ECT1 cells with vectors expressing wild-type of YAP1 protein; hCerEC-
YAPS127A and ECT1-YAPS127A cells were generated by transfecting hCerEC and ECT1 cells with vectors expressing constitutively
active YAP1 (YAPS127A, Serine at residue 127 is replaced by an Alanine resulting in the constitutive activation of YAP1). Since hCerEC
are primary cells, all experiments using hCerEC-MX, hCerEC-YAP and hCerEC-YAPS127A cells were performed within 4 passages
after transfection. Expression of YAP1 gene was confirmed by both RT-PCR and western blot assay.
Gene Silencing by siRNA
For gene silencing experiments, hCerEC, ECT1, or SiHa cells were transfected with scrambled control siRNA (siGENOME Non-
Targeting siRNA #1, D-001210-01-20) or YAP1 specific siRNAs (siYAP), or ITGA6 specific siRNAs (siITGA6) for 6 hours using Lipo-
fectamine 2000 protocol (Invitrogen, Carlsbad, CA) after cells reaching 60%confluent. siRNAs targeting YAP1 and ITGA6 geneswere
from Dharmacon (Lafayette, CO). At least two different siRNAs for each gene were used to validate the knockdown efficiency of
ITGA6 specific siRNAs. Gene knockdown was detected by RT-PCR and western blot. The results for validation of YAP1 siRNAs
were presented in supplemental Figures S12A–S12C. The results for validation of ITGA6 siRNAs were presented in supplemental
Figures S12D–S12E.
Preparation of HPV PsVs
HPV PsVs (HPV16- PsV) is a HPV16 virion-like particle in which HPV16 L1 and L2 proteins encapsulate a GFP plasmid (reporter gene).
Infection efficiency of HPV16 is indicated by the signal intensity of GFP and the ratio of GFP-positive cells in HPV16-PsV treated cells.
Previous studies have demonstrated that this PsV could well mimic HPV infection process (Conway andMeyers, 2009; Roberts et al.,
2007). HPV16-PsVwere generatedasdescribedpreviously13,59. Briefly, plasmids expressingHPVcapsid proteins L1 andL2 (p16L1L2,
#45291, Addgene. Donated by Dr. John T. Schiller’s Lab) and GFP reporter (pCIneoEGFP, #46949, Addgene. Donated by Dr. John T.
Schiller’s Lab) were co-transfected into 293TT cells using a Lipofectamine 2000 (#11668027, Invitrogen) protocol. After 48 hours, the
transfected cells were trypsinized, washedwith DPBS-Mg solution for three times, and re-suspendwith a cell concentration of 13 108
cells/ml in DPBS-Mg solution (with 0.5% Brij58, 0.2% Benzonase, and 0.2% Plasmid Safe). Cell lysate was incubated at 37C for 24
hours to ensure capsid maturation and then chilled on ice for 10 minutes. After chilling on ice, the salt concentration of the cell lysate
was adjusted to 850 mM NaCl and incubated on ice for 10 more minutes. The lysate was then clarified by centrifugation, and the
supernatant was layered onto an Optiprep gradient. The gradient was spun for 4.5 hours at 16C at 40,000 RPM in a SW40 rotor
(BeckmanCoulter, Inc.,Brea,CA). TheconcentrationofHPVPsVswasevaluatedbyanalysisofGFP transductionefficiency in293cells.
HPV16 PsV Infection of Cells
hCerEC, ECT1 or SiHa Cells (2x104 cells / well) were seeded in a 12-well plate and cultured overnight. HPV16 PsVs (1.0 or 2.0 MOI)
were added into culture medium and incubated for 72 hours. GFP signal was captured using a Nikon-ECLIPSE NI with X-CITE
system. The images were analyzed using Zeiss Zen 2010 software (Carl Zeiss Microscopy, Thornwood, NY).
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QUANTIFICATION AND STATISTICAL ANALYSIS
All experiments were repeated at least four times unless otherwise noted. Data are presented as mean ± SEM. Statistical analysis
was conducted, and graphs were made with GraphPad Prism 7.04 (GraphPad Software, Inc. La Jolla, CA). Data were analyzed
for significance using Student’s t test (two groups) or one-way ANOVA with Tukey’s post hoc tests (multiple groups). A value of
p < 0.05 was considered statistically significant.
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